Publications by authors named "Jonathan Riess"

Claim this Profile
T
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Alison M Schram, Abdul Rafeh Naqash, Eric B Haura, Jonathan W Riess, Susanna V Ulahannan

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast.
Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Jonathan W Riess

Oncol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DLL3 Immunohistochemical Expression in Neuroendocrine-Transformed -Mutant Lung Cancer and Two Cases of Tarlatamab Therapy.
Jacqueline V Aredo, Surbhi Singhal, Gerald J Berry, Farshad Moradi, Heather A Wakelee, Jonathan W Riess

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.
Fangdi Sun, Seema Nagpal, Surbhi Singhal, Joel W Neal, Heather A Wakelee, Jonathan W Riess

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke, Jonathan W Riess

Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older Adult Participation in Early-Phase Lung Cancer Clinical Trials, 1998 to 2020.
Desirae Ehley, Lilit Vardanyan, Rebecca S Boxer, Alex J Fauer, Shiruyeh Schokrpur, Jonathan W Riess

JTO Clin Res Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Epidermal Growth Factor Receptor Amplification: Passenger or Partner? Rethinking Biomarkers in Postosimertinib Strategy.
Jonathan W Riess

JCO Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
Xiuning Le, Christina Baik, Byoung Chul Cho, Jonathan W Riess, Zofia Piotrowska

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Plasma Lipidomics Reveals Distinct Signatures Following Surgery in Patients with Glioblastoma.
John Paul Aboubechara, Yin Liu, Oliver Fiehn, Lina A Dahabiyeh, Ruben Fragoso, Jonathan W Riess

Metabolites· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatment.
Kevin Lu, John Paul Shen, Fernando J Lopez-Diaz, Alessandro Leal, Isa Mambetsariev, Jonathan W Riess

NPJ Precis Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options.
Paul K Paik, Jianjun Zhang, Howard Jack West, Jonathan W Riess

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
James Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, Kien Hung Do, Piyada Sitthideatphaiboon, Jonathan W Riess

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024.
Narjust Florez, Sandip Patel, Heather A Wakelee, Julia Rotow, Elaine Shum, Jonathan Wesley Riess

Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.
Gregory J Riely, Douglas E Wood, Dara L Aisner, Billy W Loo, Andrea L Axtell, Jonathan Riess

J Natl Compr Canc Netw· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Actionable mutations and targeted therapy in non-small cell lung cancer among Latin American and Hispanic patients: a systematic literature review of prognosis and meta-analysis.
Juan Pablo Castañeda-González, Jonathan W Riess, María Paula Gómez-Gómez, Daniel Clavijo Cabezas, Merideidy Plazas Vargas

Transl Lung Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT.
Clemens Mingels, Mohammad H Madani, Fatma Sen, Hande Nalbant, Jonathan W Riess

Eur J Nucl Med Mol Imaging· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
Juan Pablo Castañeda-González, Rafael Parra-Medina, Jonathan W Riess, David R Gandara, Luis G Carvajal-Carmona

Clin Lung Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Jonathan W Riess, Adrianus J de Langen, Santiago Ponce, Sarah B Goldberg, Zofia Piotrowska

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.
Jonathan W Riess, Matthew S Lara, Guillaume Luxardi, Miguel Lopez de Rodas, Michiko Shimoda

JTO Clin Res Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Gregory J Riely, Douglas E Wood, Billy W Loo, Dara L Aisner, Wallace Akerley, Jonathan Riess

J Natl Compr Canc Netw· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.
Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen

Oncologist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis.
Matthew S Lara, Jonathan W Riess, Guneet Kaleka, Alexander Borowsky, John D McPherson

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, Jonathan W Riess

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
David R Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner, Miles C Andrews, Jonathan W Riess

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRAS G12C Inhibitors: New Drugs, A New Hope.
Surbhi Singhal, Shiruyeh Schokrpur, David Gandara, Jonathan W Riess

J Thorac Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis